A previous clinical study conducted by our research team showed that first-line chemotherapy with albumin-paclitaxel plus S-1 resulted in prolonged PFS in patients with HER-2-negative advanced gastric cancer, compared with first-line chemotherapy with oxaliplatin plus S-1 (22). This evidence concerns the gene ERBB2 and gastric cancer.